← Eichor
Condition: Non Muscle Invasive Bladder Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Muscle Invasive Bladder Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05126472Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NA · 8 location(s) · Tianjin Medical University Second Hospital · NCT07180212Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Phase N/A · 6 location(s) · University of Washington · NCT07225127Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 · 3 location(s) · Tianjin Medical University Second Hospital · NCT07475403To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients Wi
Phase 1/Phase 2 · 6 location(s) · RemeGen Co., Ltd. · NCT06378242Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NA · 1 location(s) · University of Aarhus · NCT07339761Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Chemoablation for Low-Grade Bladder Cancer
Phase 2 · 1 location(s) · Ekaterina Laukhtina · NCT07019220Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
Phase N/A · 1 location(s) · University of Zurich · NCT07494864Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Phase 1/Phase 2 · 59 location(s) · Janssen Research & Development, LLC · NCT05316155Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can
Phase 3 · 103 location(s) · Ferring Pharmaceuticals · NCT06510374Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Phase N/A · 1 location(s) · Jørgen Bjerggaard Jensen · NCT05337397A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unr
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07424287A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Pati
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07036731Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder
Phase 2 · 71 location(s) · Protara Therapeutics · NCT05951179Blue Light Cystoscopy With Cysview® Registry
Phase N/A · 23 location(s) · Photocure · NCT02660645Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Phase 2 · 7 location(s) · CHU de Quebec-Universite Laval · NCT05327647Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Phase N/A · 1 location(s) · Yunnan Cancer Hospital · NCT06972771Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Blad
Phase 2 · 46 location(s) · Tyra Biosciences, Inc · NCT06995677Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladde
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT07646145Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06551233Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
NA · 1 location(s) · Lahey Clinic · NCT07187063A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Phase 1/Phase 2 · 20 location(s) · SURGE Therapeutics · NCT05710848A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · 68 location(s) · Pfizer · NCT07206225Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bl
Phase N/A · 23 location(s) · Convergent Genomics, Inc. · NCT07673016A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT05410730The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non
Phase N/A · 2 location(s) · Tianjin Medical University Second Hospital · NCT07130578Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Phase 1 · 3 location(s) · Washington University School of Medicine · NCT06529822
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.